Organigram
Publicly traded Canadian LP with major BAT ownership stake and multi-brand portfolio.
Organigram is one of Canada's largest licensed producers by scale and market presence. Its SHRED brand has real sales volume, but 'best-selling' claims depend entirely on which data you trust and which province or time period you're measuring. The company faced serious pesticide-recall litigation in 2017–2018 that remains live. Check lot-specific COAs before buying, not just the brand name.
What it is
Organigram is a licensed producer (LP) and publicly traded cannabis company operating in Canada under the Cannabis Act and provincial regulations Strong evidence[1]. The company cultivates, processes, and packages cannabis flower, pre-rolls, vapes, edibles, and concentrates for the Canadian recreational market, and conducts medical exports where permitted [1].
Its primary production facility is located in Moncton, New Brunswick. Through acquisitions, Organigram has expanded operations to include cultivation and processing sites in Winnipeg, Manitoba (acquired through Laurentian Organic in 2023) and Lac-Supérieur, Quebec (Motif Labs/Edibles & Infusions Corp.) [2].
Ownership and corporate structure
Organigram is publicly traded on the Toronto Stock Exchange and Nasdaq under the ticker OGI Strong evidence[1].
In March 2021, British American Tobacco (BAT), through subsidiary BT DE Investments Inc., acquired approximately 19.9% of Organigram for roughly C$221 million in equity investment. The two companies established a joint Product Development Collaboration centre in Moncton Strong evidence[2][3].
For current ownership structure, corporate governance, and any subsequent transactions, readers should consult Organigram's continuous disclosure filings on SEDAR+ (the Canadian Securities Administrators' filing system) and the company's investor relations page, as shareholdings and structure evolve Strong evidence[1].
Brands and product portfolio
Organigram operates multiple consumer brands targeting different price points and product categories in the Canadian adult-use market [1]:
- Edison — flagship flower and pre-roll brand positioned in the mainstream to premium segment.
- SHRED — milled-flower and pre-roll product line emphasizing convenience and value; cited in industry reports as a high-volume seller [1].
- Big Bag O' Buds — large-format flower offering at value price points.
- Holy Mountain — flower and pre-roll brand acquired with Laurentian Organic in 2023 [2].
- Edison Edibles, Monjour, Trailblazer, Tremblant Cannabis — brands in edibles, vapes, and other categories; availability varies by period and province [1].
Product availability, SKU counts, and brand presence in provincial retail systems change frequently. Any specific product list should be treated as a snapshot. Check the provincial online ordering system or licensed retailers for current stock.
Market presence and awards
Organigram reports that SHRED and other brands rank among top sellers by volume in certain Canadian markets and has been cited in third-party industry data (e.g., market-research reports from firms tracking provincial sales) [1]. However, market-share rankings are volatile, depend on data sources, time windows, and provincial definitions, and are often self-reported or derived from partial data sets Disputed.
The company has won recognition at industry events such as the Canadian Cannabis Awards. Such awards are typically voted by industry participants and consumers and should not be interpreted as independent quality or safety certifications Weak / limited[1].
Regulatory history and controversies
2016–2017 Pesticide Recall
In 2016–2017, Organigram conducted a voluntary recall of medical cannabis products after Health Canada testing identified unauthorized pesticides (including myclobutanil and bifenazate) in certain lots Strong evidence[1]. This occurred during an industry-wide period in which multiple Canadian LPs faced pesticide-related recalls.
The recall led to litigation. A class action was certified by the Nova Scotia Court of Appeal in Downton v. Organigram Holdings Inc. (2020 NSCA 38), on behalf of medical patients who purchased affected products Strong evidence[2].
2018 Securities Class Action
In 2018, the Ontario Superior Court certified a separate securities class action alleging misrepresentations connected to the recall and product testing. This litigation has proceeded through various procedural stages Strong evidence[3].
Readers interested in the current status of these legal proceedings should consult court records directly via CanLII or the relevant provincial superior courts.
Availability and legal-market notes
Organigram products are distributed through provincial wholesalers and sold by licensed retailers across Canada's adult-use market in compliance with the federal Cannabis Act and provincial regulations Strong evidence.
The company also reports medical cannabis exports to Germany, Australia, the United Kingdom, and Israel under those jurisdictions' regulated medical-cannabis frameworks [1]. Availability in any province or country depends on provincial listings, international import licensing, and retail stock levels and is not guaranteed.
Canadian licensed producers, including Organigram, cannot legally ship cannabis products directly to consumers across provincial borders or internationally outside of regulated medical-export channels. Any claim of interprovincial or international direct-to-consumer shipping by an LP is operating outside the legal framework.
What to verify before relying on brand claims
Before accepting marketing claims about Organigram or its products, verify:
- Current ownership and corporate structure: Check SEDAR+ filings and the company's investor relations page for the latest disclosure [1].
- Product-specific Certificates of Analysis (COAs): Request the COA for the specific lot you are purchasing. Total THC, cannabinoid profile, terpene content, and contaminant testing vary batch to batch. Lab results are more informative than brand names Strong evidence.
- Strain/cultivar genetics claims: Licensed producers often use widely circulated names; the actual chemovar (cannabinoid and terpene profile on the COA) is more reliable than packaging claims Strong evidence.
- 'Best-selling' or market-share claims: Always ask for the specific data source, geography (which province or national), time period, and methodology. Market-share figures are not standardized and depend on the analyst and data source Disputed.
- Recall history: Check the Health Canada cannabis recalls database before assuming any LP has a clean record on a given product line Strong evidence[1].
This profile was last verified in October 2026.
Sources
- Government Government of Canada. Cannabis Act (S.C. 2018, c. 16) and Cannabis Regulations.
- Government Canadian Securities Administrators. SEDAR+ — Organigram Holdings Inc. / Organigram Global Inc. continuous disclosure filings.
- Reported Reuters. 'British American Tobacco buys 19.9% stake in Canada's Organigram,' 11 March 2021.
- Reported Organigram Holdings Inc. 'Organigram to Acquire Laurentian Organic Inc.' Press release, 2023.
- Peer-reviewed Downton v. Organigram Holdings Inc., 2020 NSCA 38. Nova Scotia Court of Appeal decision on class action certification.
- Government Health Canada. Recalls and safety alerts — cannabis. Searchable database of product recalls.
- Government Health Canada. Recall notices regarding Organigram Inc. medical cannabis products (2016–2017).
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Jushi Holdings — Publicly traded US cannabis operator with retail and cultivation in multiple state markets...
- TerrAscend — Publicly traded North American cannabis company with retail and wholesale operations acros...
- Tilray Brands — Publicly traded holding company operating cannabis and beverage brands across multiple jur...